Puk16 - Cost-Effectiveness of Tolvaptan in Canadian Patients With Autosomal Polycystic Kidney Disease: An Adaptation of the Adpkd Outcomes Model

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2814
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Computed Tomography in Autosomal Dominant Polycystic Kidney Disease (Adpkd)

Journal of Evolution of Medical and Dental Sciences
2015English

Cellular Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Fibroblasts

Cilia
Cell Biology
2012English

Ectopic Autosomal Dominant Polycystic Kidney Disease (ADPKD)—An Extremely Rare Radiological Finding

Open Journal of Radiology
2014English

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Kidney International Reports
Nephrology
2018English

Idiosyncratic Hepatic Toxicity in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patient in Combined Treatment With Tolvaptan and Amoxicillin/Clavulanic Acid: A Case Report

BMC Nephrology
Nephrology
2019English

Acute Pulmonary Thromboembolism Occurring During Treatment With Tolvaptan in a Patient With Autosomal-Dominant Polycystic Kidney Disease

CEN Case Reports
Nephrology
2017English

Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With a Focus on Imaging

Praxis
Medicine
2018English

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease

Drug Metabolism and Disposition
PharmacologyPharmaceutical Science
2018English

Ciliary Exclusion of Polycystin-2 Promotes Kidney Cystogenesis in an Autosomal Dominant Polycystic Kidney Disease Model

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy